| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 14/02/23 | GSK | 07:00:01 | 14 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 14/02/23 | GSK | 07:00:01 | 14 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 10/02/23 | GSK | 15:30:06 | 10 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 10/02/23 | GSK | 07:05:01 | 10 Feb 2023 | | GSK | Jemperli full FDA approval following GARNET trial | GSK PLC | RNS |
| 10/02/23 | GSK | 07:00:02 | 10 Feb 2023 | | GSK | Jemperli FDA ODAC positive outcome | GSK PLC | RNS |
| 02/02/23 | GSK | 07:00:02 | 2 Feb 2023 | | GSK | Daprodustat approved by US FDA for anaemia of CKD | GSK PLC | RNS |
| 01/02/23 | GSK | 15:30:01 | 1 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 01/02/23 | GSK | 15:00:00 | 1 Feb 2023 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/02/23 | GSK | 07:05:01 | 1 Feb 2023 | | GSK | Benlysta granted Orphan Drug Designation by US FDA | GSK PLC | RNS |
| 01/02/23 | GSK | 07:00:07 | 1 Feb 2023 | | GSK | Final Results | GSK PLC | RNS |
| 18/01/23 | GSK | 15:30:01 | 18 Jan 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/01/23 | GSK | 15:30:01 | 17 Jan 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 16/01/23 | GSK | 15:30:00 | 16 Jan 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/01/23 | GSK | 15:30:00 | 13 Jan 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/01/23 | GSK | 15:30:00 | 12 Jan 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 03/01/23 | GSK | 15:00:01 | 3 Jan 2023 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 22/12/22 | GSK | 15:30:00 | 22 Dec 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 21/12/22 | GSK | 15:35:01 | 21 Dec 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 21/12/22 | GSK | 15:30:01 | 21 Dec 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/12/22 | GSK | 15:30:12 | 15 Dec 2022 | | GSK | Board and Committee Changes | GSK PLC | RNS |
| 13/12/22 | GSK | 15:30:00 | 13 Dec 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 07/12/22 | GSK | 07:00:02 | 7 Dec 2022 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 05/12/22 | GSK | 16:00:01 | 5 Dec 2022 | | GSK | Transfer of Treasury Shares | GSK PLC | RNS |
| 02/12/22 | GSK | 15:30:03 | 2 Dec 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 02/12/22 | GSK | 07:00:06 | 2 Dec 2022 | | GSK | EMA file accepted for momelotinib | GSK PLC | RNS |
| 02/12/22 | GSK | 07:00:05 | 2 Dec 2022 | | GSK | Jemperli positive trial in endometrial cancer | GSK PLC | RNS |
| 01/12/22 | GSK | 15:00:04 | 1 Dec 2022 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 24/11/22 | GSK | 15:00:00 | 24 Nov 2022 | | GSK | GSK publishes provisional 2023 dividend dates | GSK PLC | RNS |
| 22/11/22 | GSK | 07:00:01 | 22 Nov 2022 | | GSK | Blenrep US Update | GSK PLC | RNS |
| 21/11/22 | GSK | 15:30:00 | 21 Nov 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/11/22 | GSK | 16:00:01 | 15 Nov 2022 | | GSK | Block listing Interim Review | GSK PLC | RNS |
| 11/11/22 | GSK | 07:00:06 | 11 Nov 2022 | | GSK | GSK Update: Zejula 2L in US | GSK PLC | RNS |
| 10/11/22 | GSK | 18:10:37 | 10 Nov 2022 | | GSK | Sanofi-GSK COVID booster vaccine approved by EU | GSK PLC | RNS |
| 10/11/22 | GSK | 15:30:00 | 10 Nov 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 10/11/22 | GSK | 09:00:01 | 10 Nov 2022 | | GSK | Block Listing Application | GSK PLC | RNS |
| 07/11/22 | GSK | 07:00:04 | 7 Nov 2022 | | GSK | DREAMM-3 phase III trial for Blenrep | GSK PLC | RNS |
| 03/11/22 | GSK | 07:00:14 | 3 Nov 2022 | | GSK | IDMC recommends gepotidacin early efficacy stop | GSK PLC | RNS |
| 02/11/22 | GSK | 07:01:01 | 2 Nov 2022 | | GSK | 3rd Quarter Results | GSK PLC | RNS |
| 02/11/22 | GSK | 07:00:07 | 2 Nov 2022 | | GSK | GSK RSV vaccine: US FDA Priority Review | GSK PLC | RNS |
| 01/11/22 | GSK | 15:00:02 | 1 Nov 2022 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 28/10/22 | GSK | 07:00:03 | 28 Oct 2022 | | GSK | EMA accepts GSK RSV older adult vaccine for review | GSK PLC | RNS |
| 28/10/22 | GSK | 07:00:03 | 28 Oct 2022 | | GSK | EMA validates MAA for cabotegravir LA for PrEP | GSK PLC | RNS |
| 27/10/22 | GSK | 07:05:01 | 27 Oct 2022 | | GSK | GSK announces FDA meeting outcome on daprodustat | GSK PLC | RNS |
| 27/10/22 | GSK | 07:00:01 | 27 Oct 2022 | | GSK | ContRAst phase III programme for otilimab update | GSK PLC | RNS |
| 25/10/22 | GSK | 10:00:00 | 25 Oct 2022 | | GSK | Board Committee Changes | GSK PLC | RNS |
| 21/10/22 | GSK | 07:00:01 | 21 Oct 2022 | | GSK | RSV older adult vaccine submission in Japan | GSK PLC | RNS |
| 17/10/22 | GSK | 07:00:08 | 17 Oct 2022 | | GSK | Menveo new single-vial approved by US FDA | GSK PLC | RNS |
| 14/10/22 | GSK | 14:11:34 | 14 Oct 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/10/22 | GSK | 12:46:46 | 13 Oct 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |